Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes - PubMed (original) (raw)
. 1995 Nov 10;270(45):26802-6.
doi: 10.1074/jbc.270.45.26802.
Affiliations
- PMID: 7592920
- DOI: 10.1074/jbc.270.45.26802
Free article
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes
E C Lerner et al. J Biol Chem. 1995.
Free article
Abstract
Ras-induced malignant transformation requires Ras farnesylation, a lipid posttranslational modification catalyzed by farnesyltransferase (FTase). Inhibitors of this enzyme have been shown to block Ras-dependent transformation, but the mechanism by which this occurs remains largely unknown. We have designed FTI-276, a peptide mimetic of the COOH-terminal Cys-Val-Ile-Met of K-Ras4B that inhibited potently FTase in vitro (IC50 = 500 pM) and was highly selective for FTase over geranylgeranyltransferase I (GGTase I) (IC50 = 50 nM). FTI-277, the methyl ester derivative of FTI-276, was extremely potent (IC50 = 100 nM) at inhibiting H-Ras, but not the geranylgeranylated Rap1A processing in whole cells. Treatment of H-Ras oncogene-transformed NIH 3T3 cells with FTI-277 blocked recruitment to the plasma membrane and subsequent activation of the serine/threonine kinase c-Raf-1 in cells transformed by farnesylated Ras (H-RasF), but not geranylgeranylated, Ras (H-RasGG). FTI-277 induced accumulation of cytoplasmic non-farnesylated H-Ras that was able to bind Raf and form cytoplasmic Ras/Raf complexes in which Raf kinase was not activated. Furthermore, FTI-277 blocked constitutive activation of mitogen-activated protein kinase (MAPK) in H-RasF, but not H-RasGG, or Raf-transformed cells. FTI-277 also inhibited oncogenic K-Ras4B processing and constitutive activation of MAPK, but the concentrations required were 100-fold higher than those needed for H-Ras inhibition. The results demonstrate that FTI-277 blocks Ras oncogenic signaling by accumulating inactive Ras/Raf complexes in the cytoplasm, hence preventing constitutive activation of the MAPK cascade.
Similar articles
- Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
Lerner EC, Qian Y, Hamilton AD, Sebti SM. Lerner EC, et al. J Biol Chem. 1995 Nov 10;270(45):26770-3. doi: 10.1074/jbc.270.45.26770. J Biol Chem. 1995. PMID: 7592913 - A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. Vogt A, et al. J Biol Chem. 1995 Jan 13;270(2):660-4. doi: 10.1074/jbc.270.2.660. J Biol Chem. 1995. PMID: 7822292 - [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K. Yoshimatsu K. Gan To Kagaku Ryoho. 1997 Sep;24(11):1495-502. Gan To Kagaku Ryoho. 1997. PMID: 9309147 Review. Japanese.
Cited by
- Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors.
Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB. Turner SJ, et al. Biochem Pharmacol. 2008 Jan 15;75(2):405-13. doi: 10.1016/j.bcp.2007.08.031. Epub 2007 Sep 1. Biochem Pharmacol. 2008. PMID: 17920041 Free PMC article. - Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Odeniyide P, et al. Oncogene. 2022 May;41(21):2973-2983. doi: 10.1038/s41388-022-02305-x. Epub 2022 Apr 22. Oncogene. 2022. PMID: 35459782 Free PMC article. - Inhibition of Ras for cancer treatment: the search continues.
Baines AT, Xu D, Der CJ. Baines AT, et al. Future Med Chem. 2011 Oct;3(14):1787-808. doi: 10.4155/fmc.11.121. Future Med Chem. 2011. PMID: 22004085 Free PMC article. Review. - Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U, Wang M, Hu J. Degirmenci U, et al. Cells. 2020 Jan 13;9(1):198. doi: 10.3390/cells9010198. Cells. 2020. PMID: 31941155 Free PMC article. Review. - New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. Denoyelle C, et al. Br J Cancer. 2003 May 19;88(10):1631-40. doi: 10.1038/sj.bjc.6600925. Br J Cancer. 2003. PMID: 12771933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous